Five Year Summary
2012
2013
2014
2015
2016
Dose sales (units)
6,141
7,299
8,561
10,252
11,931
Sales revenue ($'000)
82,627
96,774
129,363
176,088
232,492
Profit before income tax ($'000)
22,118
24,507
31,110
52,768
69,998
Net profit ($'000)
17,103
18,270
23,868
40,345
53,582
R&D investment ($'000)
5,723
6,615
7,981
8,641
10,835
Clinical investment ($'000) *
12,243
15,872
22,168
20,724
20,631
Capital investment ($'000)
1,092
3,685
6,187
1,692
1,718
Total assets at 30 June ($'000)
96,656
117,766
148,710
201,476
261,717
Total equity at 30 June ($'000)
73,548
87,684
107,583
144,636
193,504
Net tangible assets at 30 June ($'000)
57,314
59,762
60,219
76,609
110,683
Earnings per share (cents)
30.7
32.8
42.5
71.4
93.7
Dividends per share (cents)
10
12
14
20
30

* Excludes SIRFLOX amortisation expense

 

Charts



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×